J Clin Oncol 16 (5): 1669-76, 1998.[PUBMED Abstract] Peters WP, Jones RB, Vrendenburgh J, et al.: A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM).
[Abstract] Proceedings of the American Society of Clinical Oncology 15: A-149, 121, 1996.
Muss HB, Case LD, Richards F, et al.: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer.
The Piedmont Oncology Association.